Ethical problems in psychiatric research

Abstract

This article raises questions about the morality and value of experiments conducted mainly on psychiatric patient-subjects whose mental capacity and judgment are often impaired, making them incapable of giving informed consent. Its focus is on experimental studies in which psychotic symptoms in patients with schizophrenia have been knowingly exacerbated by suddenly withdrawing medications that they needed, administering known psychosis-producing substance such as L-dopa and apomorphine, and ignoring the treatment needs of those serving as experimental controls in placebo studies. Concerns are raised about the draft “Statement of Principles for Ethical Conduct” by the American College of Neuropsychopharmacology. Questions are also raised about the adequancy of current safeguards, including federal regulations, peer review, and the trivialization of “informed consent” by institutional review boards that operate under veils of secrecy. Implications for mental health policy are discussed, and suggestions are made for improving safeguards and reducing risks.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Katz J: “Ethics and clinical research” revisited: A tribute to Henry K. Beecher.Hastings Center Report 1993; 25(5):31–39.

    Google Scholar 

  2. 2.

    Annas GJ, Grodin MA (Eds.):The Nazi Doctors and the Nuremberg Code: Human Rights in Human Experimentation. New York: Oxford University Press, 1992.

    Google Scholar 

  3. 3.

    Grodin MA: Historical origins of the Nuremberg Code. In: Annas GJ, Grodin MA (Eds.):The Nazi Doctors and the Nuremberg Code: Human Rights in Human Experimentation. New York: Oxford University Press, 1992, pp. 121–144.

    Google Scholar 

  4. 4.

    Caplan AL: Are existing safeguards adequate?Journal of the California Alliance for the Mentally Ill 1994; 5(1):36–38.

    PubMed  Google Scholar 

  5. 5.

    Annas GJ: Experimentation and research.Journal of the California Alliance for the Mentally Ill 1994; 5(1): 9–11.

    PubMed  Google Scholar 

  6. 6.

    Annas GJ: The changing landscape of human experimentation: Nuremberg, Helsinki, and beyond.Health Matrix—Journal of Law and Medicine 1992; 2:119–140.

    CAS  Google Scholar 

  7. 7.

    Declaration of Helsinki IV, World Medical Association, 18th World Medical Assembly, 1964; amended Hong Kong, September, 1989. Council for International Organizations of Medical Sciences (CIOMS), Geneva, 1993.

  8. 8.

    National Commission for the Protection of Human Subjects of Bimedical and Behavioral Research:Report and Recommendations: Research Involving Those Institutionalized as Mentally Infirm [The Belmont Report]. DHEW Pub. No. (05) 78-0006. Washington, DC: U.S. Department of Health, Education and Welfare, 1979.

    Google Scholar 

  9. 9.

    45 Code of Federal Regulations (CFR) 46, 1985; revised 1991.

  10. 10.

    Agency says UCLA erred in medical experiments.Reuters, March 9, 1994.

  11. 11.

    Hilts PJ: Agency faults a UCLA study for suffering of mental patients.New York Times, March 10, 1994, p. A-1.

  12. 12.

    Garrett L: Closer tabs on human research urged.Newsday, March 11, 1994, p. A-17.

  13. 13.

    When the patient is also an experiment [Editorial].New York Times, March 14, 1994, p. A-16.

  14. 15.

    Horowitz J: For the sake of science.Los Angeles Times Magazine, September 11, 1994, pp. 16ff.

  15. 16.

    Subotnik KL, Neuchterlein KN: Prodromal signs and symptoms in schizophrenia relapse.Journal of Abnormal Psychology 1988; 97(4):405–412.

    PubMed  Article  CAS  Google Scholar 

  16. 17.

    Office for Protection from Research Risks, Division of Human Subject Protections:Evaluation of Human Subject Protections in Schizophrenia Research Conducted by the University of California, Los Angeles, Washington, DC: U.S. Department of Health and Human Services, May 11, 1994.

    Google Scholar 

  17. 18.

    Hawkins-Prince SL: Personal communication, December, 1994.

  18. 19.

    Thompson DI: Memorandum in opposition (on behalf of) Shalmah Lee Prince v. David L. Garver, M.D., et al., U.S. District Court, So. Dist. of Ohio, Western Division, October, 1995.

  19. 20.

    Becker JC: Amother's testimony.Journal of the California alliance for the Mentally Ill 1994; 5(1):17.

    PubMed  Google Scholar 

  20. 21.

    Davidson M, Keefe RSE, Mohs RC, et al.: L-dopa challenge and relapse in schizophrenia.American Journal of Psychiatry 1987; 144:934–938.

    PubMed  CAS  Google Scholar 

  21. 22.

    Department of Veterans Affairs, Bronx Medical Center: Consent forms for two-part-study: Neuroleptic withdrawal and Sinemet (L-dopa); obtained by author under FOIA [no date].

  22. 23.

    Davidson M: personal communciation, May 16, 1994.

  23. 24.

    Ogloff JRP, Otto RK: Are research participants truly informed? Readability of informed consent forms used in research.Ethics & Behavior 1991; 1(4):239–252.

    Article  Google Scholar 

  24. 25.

    Dorwart RA, Adler D, Berlant J, et al.: Taking issue: Outcomes assessment and psychiatric services.Hospital and Community Psychiatry 1994; 45(December):1165.

    PubMed  CAS  Google Scholar 

  25. 26.

    White KL:Healing the Schism: Epidemiology, Medicine and the Public's Health. New York: Springer-Verlag, 1991.

    Google Scholar 

  26. 27.

    Pinel P:A Treatise on Insanity, David DD (Trans.). New York: Hafner, 1962.

    Google Scholar 

  27. 28.

    Bockoven JS:Moral Treatment in American Psychiatry, New York: Springer, 1963.

    Google Scholar 

  28. 29.

    Meyer A:Psychobiology: A Study of Man. Springfield, IL: Charles C Thomas, 1957.

    Google Scholar 

  29. 30.

    Baruk H:Patients Are People Like Us: The Experiences of Half a Century in Neuropsychiatry. Finletter E, Ayer J (Trans.). New York: Morrow, 1978.

    Google Scholar 

  30. 31.

    Lehrman NS: Effective psychotherapy in chronic schizophrenia.American Journal of Psychoanalysis 1982; 42: 121–132.

    PubMed  Article  CAS  Google Scholar 

  31. 32.

    Lehrman NS: The bureaucratic destruction of patient’s faith in their doctors: Public psychiatry's negative lessons for general medicine.Bulletin of the New York Academy of Medicine 1994; 71:194–217.

    PubMed  Google Scholar 

  32. 33.

    Rothman KJ, Michels KB: The continuing unethical use of placebo controls.New England Journal of Medicine 1994: 331:394–398.

    PubMed  Article  CAS  Google Scholar 

  33. 34.

    Jonas H: Philosophical reflections on experimenting with human subjects. In: Freund PA (Ed.):Experimentation with Human Subjects. New York: Braziler, 1969, pp. 1–31.

    Google Scholar 

  34. 35.

    21 Code of Federal Regulations (CFR) ch. 1 (April 1, 1993 ed.): 314.126 (b) (2) (iv).

  35. 36.

    Beecher HK: Echics and clinical research.New England Journal of Medicine 1966; 274:1353–1360.

    Google Scholar 

  36. 37.

    Destro RA: Law, professionalism, and bad attitude,Journal of the California Alliance for the Mentally Ill 1994;5(1):50–53.

    PubMed  Google Scholar 

  37. 38.

    Taubes G: Use of placebo controls in clinical trials disputed.Science 1991; 267:25–26.

    Article  Google Scholar 

  38. 39.

    Katz J: Human experimentation and human rights.Health Law Symposium: St. Louis University Law Journal 1993; 38(1):7–54.

    Google Scholar 

  39. 40.

    Annas GJ:Judging medicine. Clifton, NJ: Humana, 1988, p. 331.

    Google Scholar 

  40. 41.

    Herz MI, Hawkins LL, Liberman RP, et al.:Practice Guidelines for Treatment of Patients with Schizophrenia, Work Group on Schizophrenia. Draft 1A. Washington, DC: American Psychiatric Association, June 1994.

    Google Scholar 

  41. 42.

    Hegarty JD, Baldessarini RJ, Tohen M, et al.: One hundred years of schizophrenia: A meta-analysis of the outcome literature.American Journal of Psychiatry 1994; 151:1409–1416.

    PubMed  CAS  Google Scholar 

  42. 43.

    Wyatt RJ: Neuroleptics and the natural course of schizophrenia.Schizophrenia Bulletin 1991; 17(2): 325–351.

    PubMed  CAS  Google Scholar 

  43. 44.

    Van Putten T: Why do schizophrenic patients refuse to take drugs?Archives of General Psychiatry 1974; 32:67–72.

    Google Scholar 

  44. 45.

    Willwerth J: Tinkering with madness.Time, August 30, 1993, pp. 40–41.

  45. 46.

    Schizophrenic’s case spurs review of consent guidelines.Los Angeles Times, July 13, 1994, p. A-5.

  46. 47.

    Lehmann C: Family testimony reveals human dimension of UCLA schizophrenia research controversy.Psychiatric News, March 17, 1995, pp. 13–14.

    Google Scholar 

  47. 48.

    Families tell their side of suicides.Santa Monica Outlook, August 13, 1995.

  48. 49.

    Shamoo AE, Irving DN: Accountability in research using persons with mental illness.Accountability in Research 1993; 3:1–17.

    PubMed  Google Scholar 

  49. 50.

    Sharav VH, Weisburd DE (Eds): Ethics in neurobiological research with human subjects [Special issue]. {jtJournal of the California Alliance for the Mentally Ill} {dy1994}; {vn5}({sn1}):1–69.

  50. 51.

    Shamoo AE: Our responsibility toward persons with mental illness as human subjects in research.Journal of the California Alliance for the Mentally Ill 1994; 5(1):14–16.

    PubMed  Google Scholar 

  51. 52.

    Shamoo AE, Keay TJ: Ethical concerns about replase studies.Cambridge Quarterly of Health Care Ethics 1996; 5:373–386.

    PubMed  CAS  Article  Google Scholar 

  52. 53.

    Gilbert PL, Harris MJ, McAdams LA, et al.: Neuroleptic withdrawal in schizophrenic patients.Archives of General Psychiatry 1995; 52:173–186.

    PubMed  CAS  Google Scholar 

  53. 54.

    Baldessarini RJ, Viguera AC: Neuroleptic withdrawal in schizophrenic patients.Archives of General Psychiatry 1995; 52:189–191.

    PubMed  CAS  Google Scholar 

  54. 55.

    Ghaemi SN, Hundert EM: The ethics of research in mental illness.Journal of the California Alliance for the Mentally Ill 1994; 5(1):47–49.

    PubMed  Google Scholar 

  55. 56.

    Denber HCB: Tranquilizers in psychiatry. In: Freedman AM, Kaplan HI, Kaplan HS (eds.):Comprehensive textbook of psychiatry, Baltimore, MD: Williams & Wilkins, 1967, pp. 1251–1262.

    Google Scholar 

  56. 57.

    Baldessarini RJ: Chemotherapy. In: Nicholi AM (Ed.):Harvard Guide to Modern Psychiatry. Cambridge, MA: Harvard University Press, 1978, pp. 387–432.

    Google Scholar 

  57. 58.

    Breggin PR:Toxic Psychiatry: Why Therapy, Empathy, and Love Must Replace the Drugs, Electroshock, and Biochemical Theories of the “New Psychiatry” New York: St. Martin’s, 1991.

    Google Scholar 

  58. 59.

    Jeste DV, Gilbert PL, McAdams LA, et al.: Considering neuroleptic maintenance and taper on a continuum.Archives of General Psychiatry 1995; 52:209–212.

    PubMed  CAS  Google Scholar 

  59. 60.

    Wolkin A, Angrist B, Wolf A, et al.: Effects of amphetamines on local cerebral metabolism in normal and schizophrenic subjects as determined by positive emission tomography,Psychopharmacology 1987; 92(2):241–246.

    PubMed  Article  CAS  Google Scholar 

  60. 61.

    Daniel DG, Weinberger DG, Jones DW, et al.: The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia.Journal of Neuroscience 1991; 11:1907–1917.

    PubMed  CAS  Google Scholar 

  61. 62.

    Szymanski S, Lieberman J, Pollack S, et al.: Clozapine effects on neuroendocrine responses to apomorphine challenge in chronic schizophrenia.Biological Psychiatry 1995; 37(1):52–55.

    PubMed  Article  CAS  Google Scholar 

  62. 63.

    Wyatt RJ: Risks of withdrawing antipsychotic medications.Archives of General Psychiatry 1995; 52:205–208.

    PubMed  CAS  Google Scholar 

  63. 64.

    Greden JF, Tendon R: Long term treatment for lifetime disorders?Archives of General Psychiatry 1995; 52:197–200.

    PubMed  CAS  Google Scholar 

  64. 65.

    Opler LA: Conducting clinical psychiatric research in “non-research” settings.Journal of California Alliance for the Mentally Ill 1994; 5(1):30–31.

    Google Scholar 

  65. 66.

    Irving DN: Psychiatric research: Reality check.Journal of the California Alliance for the Mentally Ill 1994 5 (1):42–44.

    PubMed  Google Scholar 

  66. 67.

    Katz J: Final reflections. In: Shamoo A (Ed.).Ethics in Neurobiological Research with Human Subjects, Buffalo, NY: Gordon Breach Science, 1996, pp. 331–337.

    Google Scholar 

  67. 68.

    Klein DF, Schooler N: A statement of principles of ethical conduct for neuropsychopharmacologic research in human subjects. Draft revision, November 1995, American College of Neuropsychopharmacology.

  68. 69.

    Caplan A (eEd.):When Medicine Went Mad. totoa, NJ: Humana, 1992.

    Google Scholar 

  69. 70.

    Wertham F:A Sign for Cain. London: Robert Hale, 1966.

    Google Scholar 

  70. 71.

    Mitscherlich F, Mielke F:The Death Doctors, London: Elek, 1962.

    Google Scholar 

  71. 72.

    Muller-Hill B:Murderous Science. Oxford, UK: Oxford University Press, 1988.

    Google Scholar 

  72. 73.

    Proctor RN:Racial Hygiene: Medicine under the Nazis Cambridge, MA: Harvard University Press, 1988.

    Google Scholar 

  73. 74.

    Hilts PJ: Consensus on ethics in research is elusive.New York Times, January 15, 1995, p. 24.

  74. 75.

    Burd, S: Researchers, advocates for mental patients clash over U.S. rules.Chronicle of Higher Education, January 20, 1995, p. A29.

  75. 76.

    Horvitz LA: Ethics study focuses on mentally ill.Insight, March 27, 1995, pp. 14–17.

  76. 76.

    Lieberman JA: The moral imperatives of medical research in human subjects.Journal of the California Alliance for the Mentally Ill 1994; 5(1):40–41.

    PubMed  Google Scholar 

  77. 78.

    Goodwin FK: Questions and answers.Journal of the California Alliance for the Mentally Ill 1994; 5(1): 45–47.

    PubMed  Google Scholar 

  78. 79.

    Van Kammen DP, Kelley ME, Gurklis JA, et al.: Behavioral vs. biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.Archives of General Psychiatry 1995; 52:673–678.

    PubMed  Google Scholar 

  79. 80.

    This month in AGP.Archives of General Psychiatry 1995; 52:619.

    Google Scholar 

  80. 81.

    Lehrman NS: Astate hospital population five years after admission: A yardstick for evaluative comparison of follow-up studies.Psychiatric Quarterly 1960; 34:658–681.

    PubMed  Article  CAS  Google Scholar 

  81. 82.

    Rachlin HL, Goldman GS, Gurvitz M, et al.: Follow-up study of 317 patients discharged from Hillside Hospital in 1950.Journal of the Hillside Hospital 1956; 5:17–25.

    Google Scholar 

  82. 83.

    Lehrman NS: Follow-up of brief and prolonged psychiatric hospitalization.Comprehensive Psychiatry 1961; 2: 227–240.

    PubMed  Article  CAS  Google Scholar 

  83. 84.

    Angrist B: Ethical issues regarding prospective studies of amphetamine psychosis.Journal of the California Alliance for the Mentally Ill 1994; 5(1):32–33.

    PubMed  Google Scholar 

  84. 85.

    T.D. vNYS OMH, 626 N.Y.S. 2d 1015 (Sup. Ct. NYCnty 1995); Court order: Docket Order 5136/91 (Sup. Ct. NY Cnty) 3/20/95.

  85. 86.

    Hilts PJ: Judge tells health department to stop experiments on patients.New York Times, March 26, 1995, p. A-13.

  86. 87.

    Two courts put limits on research involving the mentally ill.Chronicle of Higher Education, March 31, 1995, p. A-27.

  87. 88.

    T.D. v. NYS OMH: Appellate Div. Order: Docket No. M-3213, 8/3/95; Appellate Div. [no docket no.] order denying motion to vacate, 1/29/96.

  88. 89.

    Lowenkron R, Zucker C: Court orders state to cease dangerous experiments on psychiatric patients. Press release, January 22, 1996, New York Lawyers for the Public Interest.

  89. 90.

    Mooney M: Halts drug testing on mental patients.Daily News, January 24, 1996, p. 12.

  90. 92.

    Thomasma, DC: Obtaining consent for research in the neurobiologically impaired.Journal of the California Alliance for the Mentally Ill 1994; 5(1):54–55.

    PubMed  Google Scholar 

  91. 93.

    Willwerth J: Madness in fine print.Time, November 7, 1994, p. 63.

  92. 94.

    Weinstein, HM:Psychiatry and the CIA: Victims of mind control. Washington, DC: APA, 1990.

    Google Scholar 

  93. 95.

    Rubenstein LS: Psychiatric experimentation: The lessons of history,Journal of the California Alliance for the Mentally Ill 1994; 5(1):22–24.

    PubMed  Google Scholar 

  94. 96.

    Hilchey T: Dr. James Watts, 90, pioneer in use of frontal lobotomy [Obituary].New York Times, November 11, 1994, p. B-7.

  95. 97.

    Wong D: Neuropsychiatric hospital on probation.Daily Bruin, April 18, 1995, p. 1.

  96. 98.

    Shuit DP: Three top officials will leave UCLA clinic.Los Angeles Times, April 19, 1995, pp. B-1, B-4.

  97. 99.

    Hilts PJ: House panel told of more tests done without consent.New York Times, May 24, 1994, p. A-13.

  98. 100.

    President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research:Summing up. Washington DC: Government Printing Office, 1983.

    Google Scholar 

  99. 101.

    Appelbaum P, Lidz C, Meisel A:Informed consent—legal theory and clinical practice, Oxford, UK: Oxford University Press, 1987.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Vera Hassner Sharav M.L.S..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lehrman, N.S., Sharav, V.H. Ethical problems in psychiatric research. The Journal of Mental Health Administration 24, 227 (1997). https://doi.org/10.1007/BF02898516

Download citation

Keywords

  • Schizophrenia
  • Ethical Problem
  • Mental Health Policy
  • Psychiatric Research
  • Belmont Report